Shimojani Licenses New Stroke Therapy From Niigata University

Published: Feb 22, 2013

SAN FRANCISCO--(BUSINESS WIRE)--Shimojani LLC, a privately held biotech company, today announced that it has acquired an exclusive license from Niigata University for worldwide development and commercialization rights to an invention that has the potential to substantially reduce the risk of hemorrhage in acute ischemic stroke patients, including those who receive tissue plasminogen activator (tPA). Risk of hemorrhage is the limiting factor associated with pharmacological or mechanical clot disruption and is believed to contribute to the severity of clinical symptoms even in untreated patients. Based on an improved animal model for stroke, a key pathway has been implicated, with validation of the importance of the pathway established in the animal model using previously described agents, both protein and small molecule. Terms of the license agreement were not disclosed.

Back to news